Valuation : United Therapeutics Corporation

Market Cap 21.89B 18.85B 17.7B 16.15B 30.35B 2,083B 30.57B 210B 81.59B 1,056B 82.19B 80.41B 3,497B P/E 2026 *
19.6x
P/E 2027 * 17.8x
Enterprise Value 18.92B 16.29B 15.29B 13.96B 26.23B 1,800B 26.42B 181B 70.51B 913B 71.03B 69.49B 3,022B EV / Sales 2026 *
6.03x
EV / Sales 2027 * 5.25x
Free-Float
53.72%
Yield 2026 *
-
Yield 2027 * -
1 day-0.99%
1 week-0.49%
Current month-1.42%
1 month-1.42%
3 months-6.29%
6 months+2.35%
Current year+4.75%
1 week 507.03
Extreme 507.03
531.76
1 month 490.8
Extreme 490.8
541.03
Current year 455.63
Extreme 455.63
609.35
1 year 375.61
Extreme 375.61
609.35
3 years 208.62
Extreme 208.6249
609.35
5 years 158.38
Extreme 158.38
609.35
10 years 74.31
Extreme 74.31
609.35
Manager TitleAgeSince
Chief Executive Officer 71 25/06/1996
President 54 25/06/2016
Director of Finance/CFO 58 12/03/2015
Director TitleAgeSince
Director/Board Member 78 31/12/2001
Chairman 71 25/06/1996
Director/Board Member 92 31/12/2001
Date Insider Type Main position Quantity % Market Cap. Importance
27/08/26 Exercice

Chief Executive Officer

28,500 0.0671%
26/08/26 Exercice

Chief Executive Officer

28,500 0.0671%
25/08/26 Exercice

Chief Executive Officer

28,500 0.0671%
Change 5-day change 1-year change 3-year change Capi.($)
-0.99%-0.49%+26.08%+127.48% 21.89B
-1.52%-7.23%+57.90%+108.72% 1,031B
-0.82%-2.63%+50.05%+64.43% 641B
+0.37%-3.06%+21.87%+74.48% 453B
-1.77%-6.24%+33.47%+33.42% 349B
+4.19%+1.69%+26.95%+44.33% 290B
-0.84%-1.73%+0.42%+11.61% 252B
-0.59%-3.15%+49.83%+67.70% 232B
-0.02%-2.04%-19.71%-53.98% 201B
+0.45%-0.27%+29.84%+91.34% 181B
Average +0.14%-2.73%+27.67%+56.95% 365.17B
Weighted average by Cap. +0.35%-3.95%+36.93%+65.39%

Financials

2026 *2027 *
Net sales 3.14B 2.7B 2.54B 2.32B 4.35B 299B 4.38B 30.08B 11.7B 151B 11.79B 11.53B 502B 3.44B 2.96B 2.78B 2.54B 4.77B 327B 4.81B 32.97B 12.83B 166B 12.92B 12.64B 550B
Net income 1.2B 1.03B 968M 884M 1.66B 114B 1.67B 11.47B 4.46B 57.78B 4.5B 4.4B 191B 1.32B 1.13B 1.07B 972M 1.83B 125B 1.84B 12.62B 4.91B 63.57B 4.95B 4.84B 211B
Net Debt -2.97B -2.56B -2.4B -2.19B -4.12B -283B -4.15B -28.48B -11.08B -143B -11.16B -10.92B -475B -3.81B -3.28B -3.08B -2.81B -5.28B -362B -5.31B -36.46B -14.19B -184B -14.29B -13.98B -608B
Logo United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. It markets and sells commercial products, including Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI), Tyvaso (treprostinil) Inhalation Solution (Nebulized Tyvaso), Remodulin (treprostinil) Injection (Remodulin), Orenitram (treprostinil) Extended-Release Tablets (Orenitram), Unituxin (dinutuximab) Injection (Unituxin) and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and Nebulized Tyvaso to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). Unituxin, an infused monoclonal antibody for the treatment of high-risk neuroblastoma and for the treatment of neuroblastoma after high-dose chemotherapy. Adcirca, an oral immediate-release tablet form of the PDE-5 inhibitor tadalafil. Its THY-100 is in preclinical development for congenital athymia.
Employees
1,400
Date Price Change Volume
31/08/26 US$510.38 -0.99% 538,523
28/08/26 US$515.46 -2.36% 266,869
27/08/26 US$527.91 +2.17% 391,005
26/08/26 US$516.68 -0.36% 254,780
25/08/26 US$518.53 +1.10% 876,497
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
510.38USD
Average target price
664.33USD
Spread / Average Target
+30.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UTHR Stock